Drugs / Solrikitug
Solrikitug
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials · 1 met primary | ||||||
| Phase 1 | NCT06868082 | Jun 2025 → Feb 2026 | — | Uniquity One (UNI) | Completed | No outcome recorded |
| Phase 1 | NCT06640920 | Apr → Oct 2024 | — | Uniquity One (UNI) | Completed | No outcome recorded |
| Phase 1 | NCT01732510 | Dec 2012 → Oct 2014 | atopic eczema | Merck Sharp & Dohme LLC | Terminated | Met primary Stop: Business |
| Phase 23 trials | ||||||
| Phase 2 | NCT06598462 | Oct 2024 → Apr 2027 expected | eosinophilic esophagitis | Uniquity One (UNI) | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06496620 | Aug 2024 → Jun 2026 overdue | chronic obstructive pulmonary disease | Uniquity One (UNI) | Recruiting | No outcome recorded |
| Phase 2 | NCT06496607 | Jul 2024 → Jun 2026 overdue | asthma | Uniquity One (UNI) | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2024-10-05 | DevPro Biopharma | Regulatory DevPro Biopharma Partners with Uniquity Bio devprobiopharma.com ↗
Uniquity Bio is emerging from stealth with an FDA acceptance of its Phase 2 investigational new drug (IND) application for solrikitug, a monoclonal antibody targeting TSLP, and up to $300 million in capital from Blackstone to advance the asset in multiple indications. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2024-10-05 | DevPro Biopharma | DevPro Biopharma Partners with Uniquity Bio devprobiopharma.com ↗ |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Solrikitug | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06496620 ↗ |
| Known as | MK-8226 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01732510 ↗ |
| Known as | NSI-8226 | “A Study to Investigate Efficacy and Safety of NSI-8226 in Healthy Participants” NCT06640920 ↗ |
| Modality | Monoclonal antibody | — CHEMBL5314882 ↗ |
| Route | Intravenous | “MK-8226 administered IV” NCT01732510 ↗ |